Purchase Order 36C24226P0084
Award Date 10/20/25
Potential Completion Date 11/20/25
Potential Value $38K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- This is a firm fixed-price delivery order awarded to Takeda Pharmaceuticals America Inc. by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 (VISN 5). The contract is for the delivery of TAKHZYRO 150 MG, a specialized pharmaceutical product, with a ceiling value of $36,984.28 and a period of performance through August 5, 2025. The contract is not set aside and is awarded under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule...
- This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awards Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price contract to supply TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE with a quantity of 2. The contract is issued against Takeda Pharmaceuticals America Inc.'s existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking place in Lexington, Massachusetts. No...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order for two packages of TAKHZYRO 150MG/ML prefilled syringes. Takeda Pharmaceuticals America Inc. will deliver the packages of the hereditary angioedema preventative medication to a location in Lexington, Massachusetts by November 1, 2023 to support VHA programs. The award was issued against Takeda Pharmaceutical Company Limited's...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price delivery order for TAKHZYRO under the company's Pharmaceuticals and Drugs General Services Administration schedule contract. TAKHZYRO will be delivered to facilities in Lexington, Massachusetts by June 7, 2024 to support treatment of hereditary angioedema. No set-aside was applied given the specialized nature of the...
- The U.S. Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order to Takeda Pharmaceuticals America Inc., a subsidiary of the global pharmaceutical company Takeda Pharmaceutical Company Limited, for the supply of the specialty medication TAKHZYRO (lanadelumab-flyo) 150mg/2mL injection. The $215,511.40 contract is part of the Pharmaceuticals and Drugs General Services Administration (GSA) Schedule 61-IB and will provide the critical treatment to VA medical facilities until...
- The Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for the supply of the specialty pharmaceutical TAKHZYRO. The contract has a potential value of $36,890.40 and a completion date of April 24, 2024. Takeda Pharmaceuticals America Inc. is a prime contractor that provides a range of pharmaceutical products, including those to treat hemophilia, immune disorders,...
- This federal contract award is for the pharmaceutical product TAKHZYRO 150 MG, which was awarded to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract, valued at $36,984.28, is a delivery order with a firm fixed-price pricing type, and the ultimate completion date is August 27, 2025. The contract was awarded by the Veterans Integrated Service Network 5, a civilian defense agency, and is part of the General...
- This firm fixed price delivery order for $36,890.40 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 to Takeda Pharmaceuticals America Inc. against the company's Pharmaceuticals and Drugs GSA Schedule contract. The order is for two 150 mg/ml, 2ml injectable syringes of TAKHZRYO to treat hereditary angioedema. Performance will take place in Lexington, Massachusetts by February 6, 2024. No set-aside was applied given the...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed-price delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for the supply of LANADELUMAB-FLYO (TAKHZYRO) 15OMG/ML INJ, SYRINGE, 2ML. This contract has a potential value of $110,671.20 and a completion date of June 6, 2024. The contract was issued against Takeda's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule....